ギランバレー症候群治療の世界市場 - 2022年～2029年

当レポートでは、世界のギランバレー症候群治療市場について調査し、市場の概要とともに、治療別、投与経路別、流通チャネル別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 ギランバレー症候群治療市場の調査手法と範囲

第2章 ギランバレー症候群治療市場-市場の定義と概要

第3章 ギランバレー症候群治療市場-エグゼクティブサマリー

• 治療別市場内訳
• 投与経路別の市場内訳
• 流通チャネル市場内訳
• 地域別市場内訳

第4章 ギランバレー症候群治療市場-市場力学

• 市場に影響を与える要因
  • 促進要因
  • 抑制要因
  • 市場機会
  • 影響分析

第5章 ギランバレー症候群治療市場-業界分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ

第6章 ギランバレー症候群治療市場-COVID-19分析

第7章 ギランバレー症候群治療市場-治療別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、治療別
• 市場魅力指数、治療別
  • 静脈内免疫グロブリン
  • 血漿交換
  • その他

第8章 ギランバレー症候群治療市場-投与経路別

• イントロダクション
• 市場規模分析、および前年比成長分析（％）、投与経路別
• 市場魅力指数、投与経路別
  • 経口
  • 非経口

第9章 ギランバレー症候群治療市場-流通チャネル別

• イントロダクション
  • 市場規模分析、および前年比成長分析（％）、流通チャネル別
  • 市場魅力指数、流通チャネル別
• 病院薬局
  • イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）
• 小売薬局
• その他

第10章 ギランバレー症候群治療市場-地域別

• イントロダクション
  • 市場規模分析、100万米ドル（2020年～2029年）、および対前年比成長分析（％）（2021年～2029年）、地域別
  • 市場魅力指数、地域別
• 北米
• 欧州
• 南米
• アジア太平洋
• 中東・アフリカ

第11章 ギランバレー症候群治療市場-競合情勢

• 主な発展と戦略
• 企業シェア分析
• 製品のベンチマーク

第12章 ギランバレー症候群治療市場-企業プロファイル

• CSL Limited
• Grifols S A
• Octapharma AG
• Kedrion Biopharma Inc
• Biotest AG

第13章 ギランバレー症候群治療市場-DataM

Market Overview

The global guillain-barre syndrome treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Guillain-Barre syndrome (GBS), also known as Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), is an acute disorder marked by paralysis of limbs, difficulty breathing moving the face, and inflammatory symptoms throughout the body caused by an immune system attack on the peripheral nervous system.

Market Dynamics

The factors influencing the global guillain-barre syndrome treatment market are the growing demand for the treatment of guillain-barre syndrome and the increasing geriatric population.

The growing demand for the treatment of guillain-barre syndrome is expected to drive the market growth in the forecast period

Guillain-Barre syndrome (GBS) is a disorder characterized by symmetrical limb weakness with hyporeflexia or areflexia and sensory disturbances and cranial nerve deficits in some patients. Guillain-Barre syndrome (GBS) is a rare, rapidly progressive disease caused by nerve inflammation (polyneuritis), which causes muscle weakness and, in some cases, complete paralysis. GBS affects about one or two people per 100,000 people each year. Its exact cause has yet to be discovered. A few days before the onset of the disease, about half of the people who get it have a gastrointestinal or respiratory infection. Strong evidence suggests that the infection triggers an immune response that damages nerve fibers, resulting in weakness and loss of sensation. The sheaths of the nerve fibers are only damaged in milder cases (like the coating around an electric wire). Furthermore, there has been an increase in infections caused by the Epstein-Barr virus, Zika virus, and other viruses because of the increased demand for treatment. According to a report published in 2019 by the Foundation for Peripheral Neuropathy, GBS affects approximately 3,000-6,000 people in the United States each year, fueling the demand for effective treatment, which is expected to drive the market during the forecast period. Improved respiratory care and novel treatment strategies like plasmaphoresis and immunoglobulin have been shown to improve outcomes.

The side effects associated with the treatment of guillain-barre syndrome are expected to hamper the market growth

IVIg is currently the only infusion medication that has been proven to treat GBS. Plasma exchange is another common GBS treatment option, in which blood plasma is removed from the body and separated from the rest of the blood cells. Though rare, IVIg infusion side effects are generally limited to headaches or flu-like symptoms such as nausea, fever, chills, and body aches. The infusion itself may cause mild side effects in some patients. Such as soreness and bruising around the injection site, a sensation of cooling running down the arm and mouth has a metallic taste. According to the 2019 American Society of Aphaeresis (ASFA) guidelines, the primary use of TPE in GBS is an ASFA category I indication. The most common adverse effects associated with TPE cited in the medical literature are allergic reactions to plasma (chills, fever, rash, hives, dyspnea, and stridor), chest pain, dizziness, headache, abdominal pain, anxiety, hypotension, nausea, and vomiting; the incidence is approximately 11% compared to those receiving a 5% albumin solution as a fluid replacement; another adverse effect is symptoms of hypocalcaemia when citrate is used as an anticoagulant.

COVID-19 Impact Analysis

Since the pandemic's start, a lot has been learned about the SARS-CoV-2 virus. Several neurological complications have been reported, studied, and linked to two distinct pathways. In COVID-19 patients, the first proposed mechanism of dissemination, hematogenous (infection of leukocytes or endothelial cells) or trans-neuronal (olfactory or other cranial nerves), causes hyposmia and hypogeusia. A cytokine storm can trigger an abnormal immune-mediated response, leading to severe neurological complications like GBS, encephalomyelitis, and encephalitis. A study conducted in Northern Italy found a significantly higher number of GBS patients and a high frequency of GBS patients with COVID-19 during the COVID-19 outbreak, indicating that SARS-CoV-2 may play a role in triggering GBS. Hence, with the increasing number of covid-19 cases, the demand for the global guillain-barre syndrome treatment market is expected to grow.

Segment Analysis

The intravenous immunoglobulins segment is expected to dominate the market growth

Intravenous immunoglobulin is the most common treatment for Guillain-Barre syndrome (IVIG). The immune system (the body's natural defences) produces harmful antibodies that attack the nerves in Guillain-Barre syndrome. IVIG is a treatment made from healthy antibodies in donated blood. This help prevents nerves from being damaged by harmful antibodies. IVIG is a type of immunoglobulin that is injected directly into a vein. The primary infusion treatment for GBS patients is intravenous immunoglobulin (IVIg). IVIg uses an IV to deliver donor plasma to the body's bloodstream. Immunoglobulins that are healthy contain antibodies that fight and dilute the GBS antibodies that harm the body's nerves. In general, IVIg treatments should be started within two to four weeks of the onset of symptoms. Furthermore, the market is expected to drive by an increase in early regulatory approvals for intravenous immunoglobulin (IVIG) products and rising government support to increase plasma yield during the forecast period.

Geographical Analysis

North America region is expected to hold the largest market share in the global guillain-barre syndrome treatment market

The increasing prevalence of guillain-barre syndrome and the high demand for effective therapy in the region are expected to boost the market growth.

For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in December 2019, the prevalence of GBS is increasing in people over 50 years old, necessitating a large demand due to the US's large geriatric population. Approximately 3,000 to 6,000 people in the United States contract GBS each year, regardless of whether they were vaccinated: 1 to 2 people out of every 100,000 people. Furthermore, the presence of major pharmaceutical companies investing in research to develop novel products and regulatory bodies such as the USFDA that raise awareness about disease and treatment are likely to contribute to market growth.

Competitive Landscape

The guillain-barre syndrome treatment market is moderately competitive with mergers, collaborations, and product launches. Some of the key players in the market are CSL Limited, Grifols S A, Octapharma AG, Kedrion Biopharma Inc, Biotest AG

CSL Limited

Overview: CSL Limited is a multinational specialty biotechnology company based in Australia that conducts research, develops, manufactures, and distributes products to treat and prevent serious human medical conditions. The company was founded in 1916.

Product Portfolio: Privigen is used to treat PI, chronic inflammatory demyelinating polyneuropathy (CIDP) in adults, and chronic immune thrombocytopenic purpura (ITP) in 15 and up. Clinical trials have shown that Privigen IVIg is both safe and effective. Privigen offers a selection of IgG antibodies.

Why Purchase the Report?

Visualize the composition of the global guillain-barre syndrome treatment market segmentation by therapeutics, by route of administration, and distribution channel highlighting the key commercial assets and players.

Identify commercial opportunities in global guillain-barre syndrome treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global guillain-barre syndrome treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global guillain-barre syndrome treatment market report would provide an access to an approx. 45+market data table, 40+figures and 185 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Guillain-Barre Syndrome Treatment Market Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Guillain-Barre Syndrome Treatment Market- Market Definition and Overview

3. Guillain-Barre Syndrome Treatment Market- Executive Summary

• 3.1. Market Snippet By Therapeutics
• 3.2. Market Snippet By Route of Administration
• 3.3. Market Snippet By Distribution Channel
• 3.4. Market Snippet By Region

4. Guillain-Barre Syndrome Treatment Market-Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers:
    • 4.1.1.1. The growing demand for the treatment of guillain-barre syndrome
  • 4.1.2. Restraints:
    • 4.1.2.1. The side effects associated with the treatment of guillain-barre syndrome
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Guillain-Barre Syndrome Treatment Market- Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs

6. Guillain-Barre Syndrome Treatment Market- COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. Guillain-Barre Syndrome Treatment Market- By Therapeutics

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
• 7.3. Market Attractiveness Index, By Therapeutics
  • 7.3.1. Intravenous Immunoglobulin*
    • 7.3.1.1.1. Introduction
    • 7.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3.2. Plasma Exchange
  • 7.3.3. Others

8. Guillain-Barre Syndrome Treatment Market-By Route of Administration

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
• 8.3. Market Attractiveness Index, By Route of Administration
  • 8.3.1. Oral
    • 8.3.1.1.1. Introduction
    • 8.3.1.1.2. Market Size Analysis, US$ Mn, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3.2. Parenteral

9. Guillain-Barre Syndrome Treatment Market- By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Retail Pharmacies
• 9.4. Other

10. Guillain-Barre Syndrome Treatment Market- By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Guillain-Barre Syndrome Treatment Market- Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Guillain-Barre Syndrome Treatment Market- Company Profiles

• 12.1. CSL Limited *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Grifols S A
• 12.3. Octapharma AG
• 12.4. Kedrion Biopharma Inc
• 12.5. Biotest AG

LIST NOT EXHAUSTIVE

13. Guillain-Barre Syndrome Treatment Market- DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us